Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma

M R Litzow, P P Peethambaram, S L Safgren, G L Keeney, S M Ansell, A Dispenzieri, M A Elliott, D A Gastineau, M A Gertz, D J Inwards, M Q Lacy, I N M Micallef, L F Porrata, W L Lingle, L C Hartmann, M H Frost, B A Barrette, H J Long, V J Suman, J M Reid, M M Ames, S H Kaufmann, M R Litzow, P P Peethambaram, S L Safgren, G L Keeney, S M Ansell, A Dispenzieri, M A Elliott, D A Gastineau, M A Gertz, D J Inwards, M Q Lacy, I N M Micallef, L F Porrata, W L Lingle, L C Hartmann, M H Frost, B A Barrette, H J Long, V J Suman, J M Reid, M M Ames, S H Kaufmann

Abstract

We designed a phase I clinical trial of escalating doses of topotecan with CY and carboplatin in combination with autologous hematopoietic SCT (AHSCT) for the treatment of relapsed or persistent platinum sensitive ovarian or primary peritoneal carcinoma. After stem cell collection, 16 patients received topotecan at 1.5, 2.5, 3.5, 4.5 or 6.0 mg/m(2)/d combined with CY 1.5 g/m(2)/d and carboplatin 200 mg/m(2)/d, all by 4-day continuous infusion. Steady state pharmacokinetics of topotecan and carboplatin were examined. Pre-treatment biopsies were examined for the expression of topoisomerase (topo) I, Ki67 and Bcl-2 family members by immunohistochemistry. One of six patients at a topotecan dose of 4.5 mg/m(2)/d and two of three patients at 6.0 mg/m(2)/d had dose-limiting toxicity of grade 3 stomatitis lasting >2 weeks. There was no treatment-related mortality. As topotecan clearance was constant over the dose range examined, topotecan steady state plasma concentrations increased with dose. Median progression-free survival and overall survival were 6.5 months and 2.7 years, respectively. Shorter progression-free survival was observed in tumors with low topo expression (P=0.04). Topotecan can safely be dose escalated to 4.5 mg/m(2)/d in combination with CY, carboplatin and AHSCT. This trial is registered at ClinicalTrials.gov as NCT00652691.

Figures

Figure 1
Figure 1
A) Graph of topotecan steady-state plasma concentration (CSS) versus topotecan dose. B) Graph of ultrafilterable platinum (Pt) steady-state plasma concentration (CSS) versus topotecan dose.
Figure 1
Figure 1
A) Graph of topotecan steady-state plasma concentration (CSS) versus topotecan dose. B) Graph of ultrafilterable platinum (Pt) steady-state plasma concentration (CSS) versus topotecan dose.

References

    1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics 2008. CA Cancer J Clin. 2008;58:71–96.
    1. McGuire WP. Treatment of advanced epithelial ovarian cancer. Clin Oncol. 2002;5:1–8.
    1. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333:1540–1545.
    1. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996;335:91–97.
    1. Stiff PJ, Bayer R, Kerger C, Potkul RK, Malhotra D, Peace DJ, et al. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients. J Clin Oncol. 1997;15:1309–1317.
    1. Stiff PJ, Veum-Stone J, Lazarus HM, Ayash L, Edwards JR, Keating A, et al. High-dose chemotherapy and autologous stem-cell transplantation for ovarian cancer: an autologous blood and marrow transplant registry report. Ann Intern Med. 2000;133:504–515.
    1. Donato ML, Aleman A, Champlin RE, Saliba RM, Wharton JR, Burke TW, et al. Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation. Bone Marrow Transplantation. 2004;33:1219–1224.
    1. Bengala C, Guarneri V, Ledermann J, Rosti G, Wandt H, Lotz JP, et al. High-dose chemotherapy with autologous haemopoietic support for advanced ovarian cancer in first complete remission: retrospective analysis from the solid tumour registry of the Europeon group for blood and marrow transplantation (EBMT) Bone Marrow Transplantation. 2005;36:25–31.
    1. Cure H, Battista C, Guastalla J, Fabbro M, Tubiana N, Bourgeois H, et al. Phase III randomized trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients (pts) with responsive low-burden advanced ovarian cancer (AOC): 5 year follow-up of a GINECO/FNCLCC/SFGM-TC Study. Proc of ASCO. 2004;22:450s. abstract 5006.
    1. Möbus V, Wandt H, Frickhofen N, Bengala C, Champion K, Kimmig R, et al. Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: Intergroup trial of the AGO-Ovar/AIO and EBMT. J Clin Oncol. 2007;25:4187–4193.
    1. Sullivan D, Partyka J, Fields K, Goldstein S, Field T, et al. A phase I study of high-dose topotecan, ifosfamide/MESNA and etoposide (TIME) followed by autologous stem cell rescue in refractory malignancies. Exp Hem. 2000;28((7):Suppl 1):110. abstract.
    1. Schilder RJ, Gallo JM, Millenson MM, Bookman MA, Weiner LM, Rogatko A, et al. Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-cell support as front-line therapy. J Clin Oncol. 2001;19:1183–1194.
    1. Park JR, Slattery J, Gooley T, Hawkins D, Lindsley K, Villablanca JG, et al. Phase I topotecan preparative regimen for high-risk neuroblastoma, high-grade glioma, and refractory/recurrent pediatric solid tumors. Med Pediatr Oncol. 2000;35:719–723.
    1. Tiersten A, Selleck M, Smith D, Wertheim I, Kaufman E, Hershman D, et al. Phase I/II study of tandem cycles of high-dose chemotherapy followed by autologous hematopoietic stem cell support in women with advanced ovarian cancer. Int J Gynecol Cancer. 2006;16:57–64.
    1. Lotz J-P, Pautier P, Selle F, Viens P, Fabbro M, et al. Phase I study of high-dose topotecan with haematopoietic stem cell support in the treatment of ovarian carcinomas: the ITOV 01 protocol. Bone Marrow Transplantation. 2006;37:669–675.
    1. Perez-Martinez A, Lassaletta A, Gonzalez-Vicent M, Sevilla J, Angel Diaz M, et al. High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors. Journal Neuro-Onc. 2005;71:33–38.
    1. Donato ML, Aleman A, Champlin RE, Weber D, Alexanian R, et al. High-dose topotecan, melphalan, cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myeloma. Leukemia & Lymphoma. 2004;45:755–759.
    1. Bernbeck B, Bahci S, Meisel R, Troeger A, Schonberger S, et al. Serial intense chemotherapy combining topotecan, etoposide, carboplatin and cyclophosphamide (TECC) followed by autologous hematopoietic stem cell support in patients with high risk soft tissue sarcoma (STS) Klin Padiatr. 219:318–322.
    1. Bookman MA, Malmstrom H, Bolis G, Gordon A, Lassoni A, Krebs JB, et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol. 1998;16:3345–3352.
    1. McGuire WP, Blessing JA, Bookman MA, Lentz SS, Dunton CJ. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol. 2000;18:1062–1067.
    1. Armstrong D. Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity. Oncologist. 2004;9:33–42.
    1. Kaufmann S, Peereboom D, Buckwalter C, Svingen PA, Grochow LB, Donehower RC, et al. Cyototoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst. 1996;88:699–700.
    1. Jonsson E, Fridborg H, Nygren P, Larsson R. Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients. Eur J Clin Pharmacol. 1998;54:509–514.
    1. Ma J, Maliepaard M, Nooter K, Boersma AW, Verweij J, Stoter G, et al. Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro. Cancer Chemother Pharmacol. 1998;41:307–316.
    1. Johnson R, McCabe FL, Yu Y. Combination regimens with topotecan in animal models. Ann Oncol. 1992;3(Suppl 1):85. abstract.
    1. Antman K, Ayash L, Elias A, Wheeler C, Hunt M, Eder JP, et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol. 1992;10:102–110.
    1. Kaufmann SH, Karp JE, Letendre L, Kottke TJ, Safgren SL, Greer J, et al. Phase I and Pharmacological Study of Infusional topotecan and Carboplatin in Relapsed and Refractory Acute Leukemia. Clin Cancer Res. 2005;11:6641–6649.
    1. Creemers GJ, Gerrits CJ, Schellens JH, Planting AS, van der Burg ME, van Beurden VM, et al. Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer. J Clin Oncol. 1996;14:2540–2545.
    1. Herben VM, ten Bokkel Huinink WW, Schot ME, Hudson I, Beijnen JH. Continuous infusion of low-dose topotecan: pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer. Anticancer Drugs. 1998;9:411–418.
    1. Pizao P, Smitskamp-Wilms E, Van Ark-Otte J, Beijnen JH, Peters GJ, Pinedo HM, et al. Antiproliferative activity of the topoisomerase I inhibitors topotecan and camptothecin, on sub- and postconfluent tumor cell cultures. Biochemical Pharmacol. 1994;48:1145–1154.
    1. Li T, Liu L. Tumor cell death induced by topoisomerase-targeting drugs. Ann Rev Pharmacol and Toxicol. 2001;41:53–77.
    1. Nitiss J, Rose A, Sykes K, Harris J, Zhou J. Using yeast to understand drugs that target topoisomerases. Ann NY Acad Sci. 1996;803:32–43.
    1. van Waardenburg R, de Jong L, van Eijndhoven MAJ, Verseyden C, Pluim D, Jansen LET, et al. Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin. J Biol Chem. 2004;279:54502–9.
    1. Walton M, Whysong D, O'Connor P, Hockenbery D, Korsmeyer SJ, Kohn KW. Constitutive expression of human bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res. 1993;53:1583–1861.
    1. Williams J, Lucas P, Griffith K, Choi M, Fogoros S, Hu YY, et al. Expression of bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol Oncol. 2005;96:287–295.
    1. Cook S, Penson R, Duska L, Nikrui N, Goodman A, Fuller A, et al. Efficacy and hematologic toxicity of salvage chemotherapy following stem cell-supported high-dose chemotherapy in women with recurrent ovarian cancer. Gynecol Oncol. 2000;77:48–54.
    1. Rowinsky E, Kaufmann S, Baker S, Grochow LB, Chen TL, Peereboom D, et al. Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. J Clin Oncol. 1996;14:3074–84.
    1. Pourquier P, Waltman J, Urasaki Y, Loktionova NA, Pegg AE, Nitiss JL, et al. Topoisomerase I-mediated cytotoxicity of N-methyl-N′-nitro-N-nitrosoguanidine: trapping of topoisomerase I by the O6-methylguanine. Cancer Res. 2001;61:53–8.
    1. Cornaratti M, Capranico G, Bohm S, Oriana S, Spatti GB, Mariani L, et al. Gene expression of DNA topoisomerases I, II alpha and II beta and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Int J Cancer. 1996;67:479–84.
    1. Materna V, Pleger J, Hoffmann U, Lage H. RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response. Gynecol Oncol. 2004;94:152–60.
    1. Schilder RJ, Brady MF, Spriggs D, Shea T. Pilot evaluation of high-dose carboplatin and paclitaxel followed by high-dose melphalan supported by peripheral blood stem cells in previously untreated advanced ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2003;88:3–8.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren